CD40 and mesothelioma: The increased regulatory status of elderly DCs and T cells may not only affect tumor progression, but also the efficacy of anti-tumor immunotherapies, which is supported by our data showing that IL-2/CD40 immunotherapy is less effective in inducing mesothelioma regression in elderly mice.